Lucid Diagnostics (LUCD) Projected to Post Quarterly Earnings on Monday

Lucid Diagnostics (NASDAQ:LUCD) is expected to be releasing its earnings data before the market opens on Monday, March 24th. Analysts expect Lucid Diagnostics to post earnings of ($0.15) per share and revenue of $1.42 million for the quarter. Persons interested in participating in the company’s earnings conference call can do so using this link.

Lucid Diagnostics Stock Down 3.2 %

Lucid Diagnostics stock opened at $1.52 on Friday. Lucid Diagnostics has a twelve month low of $0.63 and a twelve month high of $1.63. The company’s 50-day moving average price is $1.20 and its 200-day moving average price is $0.98. The company has a market cap of $90.20 million, a PE ratio of -1.33 and a beta of 1.34.

Wall Street Analysts Forecast Growth

Separately, Ascendiant Capital Markets lowered their price objective on shares of Lucid Diagnostics from $7.25 to $7.00 and set a “buy” rating for the company in a research report on Monday, December 9th. Four equities research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, the company has an average rating of “Buy” and a consensus target price of $3.63.

Lucid Diagnostics Company Profile

Lucid Diagnostics Inc operates as a commercial-stage medical diagnostics technology company in the United States. The company focuses on patients with gastroesophageal reflux disease (GERD) who are at risk of developing esophageal precancer and cancer, primarily highly lethal esophageal adenocarcinoma.